Effects of CCK-tetrapeptide in patients with social phobia and obsessive-compulsive disorder

Depression and Anxiety

Volumn 20, Issue 2, 2004, Pages 51-58

  Katzman, Martin A ^a   Koszycki, Diana ^b   Bradwejn, Jacques ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ROYAL OTTAWA HOSPITAL   (Canada)

Author keywords

CCK 4; Cholecystokinin; Obsessive compulsive disorder; Panic attacks; Social phobia

Indexed keywords

TETRAGASTRIN;

ADULT; ANXIETY; ARTICLE; BEHAVIOR; CARDIOVASCULAR FUNCTION; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; MALE; NEUROENDOCRINOLOGY; OBSESSIVE COMPULSIVE DISORDER; PANIC; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SOCIAL PHOBIA; STATISTICAL SIGNIFICANCE; SYMPTOM;

ADRENOCORTICOTROPIC HORMONE; ADULT; ANXIETY; AROUSAL; AUTONOMIC NERVOUS SYSTEM; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PANIC DISORDER; PHOBIC DISORDERS; PROLACTIN; REFERENCE VALUES; SINGLE-BLIND METHOD; TETRAGASTRIN;

EID: 7444223378     PISSN: 10914269     EISSN: None     Source Type: Journal    
DOI: 10.1002/da.20012     Document Type: Article

References (28)

1. Abelson JL, Nesse RM, Vinik AI. 1994. Pentagastrin infusions in patients with panic disorder. II. Neuroendocrinology. Biol Psychiatry 36:84-96.
2. Bradwejn J, Koszycki D, Meterissian G. 1990. Cholecystokinin tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83-85.
3. Bradwejn J, Koszycki D, Shriqui C. 1991a. Enhanced sensitivity to cholecystokinin-tetrapeptide in PD: Clinical and behavioral findings. Arch Gen Psychiatry 48:603-607.
4. Bradwejn J, Koszycki D, Bourin M. 1991b. Dose ranging study of cholecystokinin in healthy volunteers. J Psychiatr Neurosci 16:91-95.
5. Bradwejn J, Koszycki D, Annable L, Couctoux du Tertre A, Reines S, Karkanias. 1992. A dose-ranging study of the behavioural and cardiovascular effects of CCK-cetrapepcide-induced in panic disorder. Biol Psychiatry 32:903-912.
6. Bradwejn J, Koszycki D, Couteux du Tertre A, Van Meagan H, Den Boer J, Westenberg, H, Annable L. 1994. The panicogenic effects of cholecysrokinin- tetrapeptide are antagonized by L-365, 260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51: 486-493.
7. Brawman-Mintzer O, Lydiard B, Bradwejn J, Villarreal G, Knapp R, Emmanuel N, Ware MR, He Q, Ballenger JC. 1997. Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry 154:700-702.
8. Denavit-Sauhié M, Hurle MA, Morin-Surun MP, Foutz AS, Champagnat J. 1985. The effects of cholecystokinin-8 in the nucleus tractus solitarius. Ann NY Acad Sci 448:375-384.
9. de Leeuw AS, Den Boer JA, Slaap BR, Westenberg HGM. 1996. Pentagastrin has panic-inducing properties in obsessive-compulsive disorder. Psychopharmacology 126:339-344.
10. Flint A, Koszycki D, Vaccarino F, Cadieux A, Boulenger P, Bradwejn J. 1998. The effect of aging on cholecystokinin induced panic. Am J Psychiatry 155:283-285.
11. Flint AJ, Koszycki D, Bradwejn J, Vaccarino FJ. 2000. Neurohormonal response to cholecystokinin-tetrapeptide: A comparison of younger and older healthy subjects. Psychoneuroendocrinology, 25:633-647.
12. Harro J, Vasar E, Bradwejn J. 1993. CCK in animal and human research on anxiety. Trends Pharmacol Sci 14:244-249.
13. Javanmard M, Shlik J, Kennedy S, Vaccarino F, Houle S, Bradwejn J. 1999. Neuroanatomical correlates of CCK-4-induced panic attack in healthy humans: A comparison of two time points. Biol Psychiatry 45:872-882.
14. Kellner M, Wiedemann K, Yassouridis A, Levengood R, Song Guo L, Holsboer F, Yehuda R. 2000. Behavioral and endocrine response to cholecystokinin tetrapeptide in patients with posttraumatic stress disorder. Biol Psychiatry 47:107-111.
15. Koszycki D, Copen J, Bradwejn J. 2004. CCK-4 sensitivity in major depression. J Affect Disord (in press).
16. Koszycki D, Zacharko RM, Le Melledo JM, Bradwejn J. 1998. Behavioural, cardiovascular and neuroendocrine profiles following CCK-4 challenge in healthy volunteers: a comparison of panickers and non-panickers. Depress Anxiety 8:1-7.
17. Le Melledo J, Merani S, Koszycki D, Bellavance F, Palmour R, Gutkowska J, Steinberg S, Bichet DG, Bradwejn J. 1999. Sensitivity to CCK-4 in women with and without premenstrual dysphoric disorder during their follicular and luteal phases. Neuropsychopharrnacology 20:81-91.
18. Liebowitz MR, Gorman JM, Fyer AJ, Levitt AJ, Dillon M, Levy D, Appleby IL, Anderson S, Palij M, Davies SO, Klein DF. 1985. Lactate provocation of panic attacks: II. Biochemical and physiological findings. Arch Gen Psychiatry 41:764-770.
19. McCann UD, Slate SO, Geraci M, Roscow-Terill D, Uhde TW. 1997. A comparison of intravenous pentagastrin on patients with social phobia, panic disorder, and healthy controls. Neuropsychopharmacology 16:229-237.
20. 2 challenge. Am J Psychiatry 152:85-89.
21. Perna G, Gabriele A, Calidorla D, Bellodi L. 1995b. Hypersensitivity to inhalation of carbon dioxide and panic attacks. Psychiatry Res 57:267-273.
22. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. 1997. Effects of citalopram treatment on behavioural, cardiovascular, and neuroendocrine response to cholecystokinin tetrapeptide challenge in panic disorder patients. J Psychiatry Neurosci 22: 332-340.
23. Rasmussen SA, Goodman WK, Woods SW, Heninger GR, Charney DS. 1987. Effects of yohimbine in obsessive-compulsive disorder. Psychopharmacology 93:308-313.
24. Swain J, Koszycki D, Shlik J, Bradwejn J. 2003. Pharmacological challenge agents in anxiety. In: Nutt D, Ballenger J, editors. Anxiety disorders. Oxford: Blackwell Publishing. p 269-296.
25. Uhde TW, Tancer ME, Rubinow DR, Roscow DB, Boulenger J-P, Vittone B, Gurguis G, Geraci M, Black B, Post RM. 1992. Evidence for hypothalamo-growth hormone dysfunction in panic disorder: Profile of growth hormone (GH) response to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmacology 6:101-118
26. van Megen HJGM, Westenberg MGM, den Boer JA, Haigh JRM, Traub M. 1994. Pentagastrin induced panic attacks: Enhanced sensitivity in panic disorder. Psychopharmacology 114:449-255.
27. 4 in patients with panic disorder. European Neuropsychopharmacology 6:197-194.
28. van Vliet IM, Westenberg HGM, Slaap BR, den Boer JA, Ho Pian KL. 1997. Angiogenic effects of pentagastrin in patients with social phobia and healthy controls. Biol Psychiatry 42:76-78.